Your browser doesn't support javascript.
loading
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.
Barber, Fedricker D; Campbell, Erick; Yamamura, Yuko; Patterson, Clover J; Hartnett, Audrey C; Kinahan, Holly; Miller, Victoria A; Brink, Amanda L; Poullard, Anna; Urschel, Gabriele E; Brantley, Andre; Cepeda, Isabel G; Goswami, Poonam; Charles, Sheena; Philip, Shincy; Bresser, Sara; Musekiwa-Adjei, Sandra; Perez, Nageli; Le, Hung; Phillips, Penny; Subbiah, Vivek; Meric-Bernstam, Funda; Dumbrava, Ecaterina E.
Afiliação
  • Barber FD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Campbell E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yamamura Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patterson CJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hartnett AC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kinahan H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Miller VA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Brink AL; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Poullard A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Urschel GE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Brantley A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cepeda IG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Goswami P; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Charles S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Philip S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bresser S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Musekiwa-Adjei S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Perez N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Le H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Phillips P; Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dumbrava EE; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Adv Pract Oncol ; 13(7): 664-672, 2022 Sep.
Article em En | MEDLINE | ID: mdl-36199491
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Adv Pract Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Adv Pract Oncol Ano de publicação: 2022 Tipo de documento: Article